Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV) — a systematic review and individual patient data meta-analysis

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

  • Ronald Chow
  • Leyi Bellinda Yin
  • Wafa Baqri
  • Ryan Huang
  • Gabriel Boldt
  • Jawaid Younus
  • Michael Lock
  • Elizabeth Prsic
  • Camilla Zimmermann
  • Herrstedt, Jørn

Introduction: Although there have been reports of chemotherapy-induced nausea and vomiting (CINV) beyond 120 h, its overall prevalence has not been systematically examined. The aim of this review and meta-analysis was to report on the prevalence of this long-delayed CINV. Methods: This review was registered on PROSPERO (CRD42022346963). PubMed (Medline), Embase, and Cochrane Central were searched from inception until August 2022. Articles were included if they reported on CINV > 120 h after initiation of the chemotherapy regimen and patients received a single-agent highly emetogenic (HEC) or moderately emetogenic (MEC) antineoplastic agent for 1 day alone or in combination with low/minimal emetogenic chemotherapy. For all eligible articles, individual study authors were contacted and requested to provide individual patient-level data of demographics, emetogenicity of chemotherapy regimens, and daily incidence of nausea and vomiting. Forward stepwise logistic regression identified predictors for the incident day’s CINV based on prior day’s CINV episodes, controlling for patient demographics, and stratified by regimen emetogenicity. Results: A total of 2048 patients from 2 studies were included in this individual patient data meta-analysis: 1333 patients (65%) received HEC and 715 (35%) received MEC. Among those receiving HEC, 325 (24%) experienced acute, 652 (49%) delayed, and 393 (31%) long-delayed nausea; 107 (8%) experienced acute, 179 (14%) delayed, and 79 (6%) long-delayed vomiting. Among those receiving MEC, 48 (7%) experienced acute, 272 (38%) delayed, and 167 (24%) long-delayed nausea; 12 (2%) experienced acute, 97 (14%) delayed, and 42 (6%) long-delayed vomiting. Nausea in the long-delayed phase was as severe as in the delayed phase. Patients experiencing nausea and vomiting on days 4 and 5 were at significant risk of experiencing long-delayed CINV. Conclusion: While not as prevalent as delayed nausea and vomiting, long-delayed CINV affects a significant proportion of patients and severity is similar. Patients with delayed CINV, specifically on days 4–5, are at risk of experiencing long-delayed CINV.

TidsskriftSupportive Care in Cancer
Udgave nummer8
Antal sider11
StatusUdgivet - 2023

Bibliografisk note

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

ID: 371274515